Skip to main content

Advertisement

SpringerLink
Log in

Combination Therapy for the Treatment of Mucormycosis: Examining the Evidence

  • Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Despite aggressive antifungal therapy and surgical intervention, mortality and clinical response rates for invasive mucormycosis infections remain suboptimal. Combination therapy with other antifungal agents, immunosuppressive drugs, and various other agents, have been studied as a means to improve outcomes. However, most clinical outcomes data evaluating combination therapy are from case series and case reports, and the majority of comparative data derives from in vitro models and animal studies. Thus, this review evaluates the rationale and risks of various combinations for the treatment of invasive mucormycosis infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20 Suppl 3:5–26. Comprehensive European clinical guidelines on treatment of mucormycosis.

    Article  CAS  PubMed  Google Scholar 

  2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.

    Article  PubMed  Google Scholar 

  3. Sun QN, Fothergill AW, MCCarthy DI, Rinaldi MG, Graybill JR. In vivo activity of posaconazole against Mucor spp. In an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46:1581–2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Shoham S, Magill S, Merz WB, et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol. 2010;48(3):511–7.

    Article  CAS  PubMed  Google Scholar 

  6. Ibrahim AS, Gebermariam T, Schwartz JA, Edwards Jr JE, Spellberg B. Posaconazole mono- or combination therapy for the treatment of murine zygomycosis. Antimicrob Agents Chemother. 2009;53:72–5.

    Article  Google Scholar 

  7. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46(4):1032–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Gómez-López A, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother. 2001;48(6):919–21.

    Article  PubMed  Google Scholar 

  9. Gil-Lamaignere C, Hess R, Salvenmoser S, Heyn K, Kappe R, Müller FM. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother. 2005;55(6):1016–9.

    Article  CAS  PubMed  Google Scholar 

  10. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE, Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003;51(1):45–52.

    Article  CAS  PubMed  Google Scholar 

  11. Arikan S, Sancak B, Sehnaz A, Gulsen H, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol. 2008;46:567–73.

    Article  CAS  PubMed  Google Scholar 

  12. Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphothericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother. 2008;61(3):755–7.

    Article  CAS  PubMed  Google Scholar 

  13. Perkhofer S, Locher M, Cuenca-Estrella M, et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother. 2008;52(7):2636–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni G, et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012;67(8):1937–40. doi:10.1093/jac/dks137.

    Article  CAS  PubMed  Google Scholar 

  15. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003;47:3647–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Zhang S, Li R, Yu J. Drug combinations against Mucor irregularis in vitro. Antimicrob Agents Chemother. 2013;57(7):3395–7. doi:10.1128/AAC.02612-12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Guembe M, Guinea J, Peláez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother. 2007;51(9):3457–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Christenson JC, Shalit I, Welch DF, Guruswamy A, Marks MI. Synergistic action of amphotericin B and rifampin against rhizopus species. Antimicrob Agents Chemother. 1987;31(11):1775–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Biswas C, Sorrell TC, Djordjevic JT, Zuo X, Jolliffe KA, Chen SC. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. J Antimicrob Chemother. 2013;68(12):2842–6. doi:10.1093/jac/dkt282.

    Article  CAS  PubMed  Google Scholar 

  20. Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother. 2009;53(8):3549–51. doi:10.1128/AAC.00184-09.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Thakur M, Revankar SG. In vitro interaction of caspofungin and immunosuppressives against agents of mucormycosis. J Antimicrob Chemother. 2011;66(10):2312–4.

    Article  CAS  PubMed  Google Scholar 

  22. Narreddy S, Manavathu E, Chandrasekar PH, Alangaden GJ, Revankar SG. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes. J Antimicrob Chemother. 2010;65(4):701–3. doi:10.1093/jac/dkq020.

    Article  CAS  PubMed  Google Scholar 

  23. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother. 2006;50(1):96–103.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009;47(12):3797–804. doi:10.1128/JCM.00618-09.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Lewis RE, Ben-Ami R, Best L, et al. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. J Infect Dis. 2013;207(5):834–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Investig. 2007;117(9):2649–57.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryze. Antimicrob Agents Chemother. 2008;52:3786–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Spellberg B, Fu Y, Edwards Jr JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49(2):830–2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Ibrahim AS, Gebremariam T, Fu Y, Edwards Jr JE, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556–8. doi:10.1128/AAC.01458-07.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Ibrahim AS, Gebremariam T, Luo G, Fu Y, French SW, Edwards Jr JE, et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother. 2011;55(4):1768–70. doi:10.1128/AAC.01577-10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Saoulidis S, Simitsopoulou M, Dalakiouridou M, et al. Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model. Mycosis. 2011;54(5):e486–92.

    Article  Google Scholar 

  32. Vazquez L, Mateos JJ, Sanz-Rodriguez C, Perez E, Caballero D, San Miguel JF. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica. 2005;90(12 Suppl):ECR39.

    CAS  PubMed  Google Scholar 

  33. Ojeda-Uribe M, Herbrecht R, Kiefer MH, Schultz P, Chain J, Chenard MP, et al. Lessons from a case of oromandibular mucormycosis treated with surgery and a combination of amphotericin B lipid formulation plus caspofungin. Acta Haematol. 2010;124(2):98–102. doi:10.1159/000315675.

    Article  CAS  PubMed  Google Scholar 

  34. Ogawa T, Takezawa K, Tojima I, Shibayama M, Kouzaki H, Ishida M, et al. Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin. Auris Nasus Larynx. 2012;39(2):224–8. doi:10.1016/j.anl.2011.03.006.

    Article  PubMed  Google Scholar 

  35. Kazak E, Aslan E, Akalın H, Saraydaroğlu O, Hakyemez B, Erişen L, et al. A mucormycosis case treated with a combination of caspofungin and amphotericin B. J Mycol Med. 2013;23(3):179–84. doi:10.1016/j.mycmed.2013.06.003.

    Article  CAS  PubMed  Google Scholar 

  36. Reed C, Bryant R, Ibrahim AS, Edwards Jr J, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–71. doi:10.1086/589857.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Lebeau O, Van Delden C, Garbino J, et al. Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection. Transpl Infect Dis. 2010;12:269–72.

    Article  CAS  PubMed  Google Scholar 

  38. Rickerts V, Atta J, Herrmann S, et al. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses. 2006;49(1):27–30.

    Article  PubMed  Google Scholar 

  39. Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Abuali MM, Posada R, Del Toro G, et al. Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia. J Clin Microbiol. 2009;47(12):4176–9.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Reed C, Ibrahim A, Edwards Jr JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50(11):3968–9.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Soummer A, Mathonnet A, Scatton O, Massault PP, Paugam A, Lemiale V, et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother. 2008;52(4):1585–6. doi:10.1128/AAC.01611-07.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Busca A, Marmont F, Locatelli F, Limerutti G, Sorrentino MT, Barbui A, et al. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses. 2010;53(3):275–8. doi:10.1111/j.1439-0507.2009.01708.x.

    Article  PubMed  Google Scholar 

  44. Ting JY, Chan SY, Lung DC, Ho AC, Chiang AK, Ha SY, et al. Intra-abdominal Rhizopus microsporus infection successfully treated by combined aggressive surgical, antifungal, and iron chelating therapy. J Pediatr Hematol Oncol. 2010;32(6):e238–40. doi:10.1097/MPH.0b013e3181e622bf.

    Article  PubMed  Google Scholar 

  45. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53(7):3122–5. doi:10.1128/AAC.00361-09.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715–22. doi:10.1093/jac/dkr375. Only randomized, double-blinded placebo-controlled trial evaluating combination therapy for treatment of mucormycosis.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Riberio EF, dos Santos VM, Paixao GT, et al. Mucormycosis in a patient with acute myeloid leukemia successfully treated with liposomal amphotericin B associated with deferasirox and hyperbaric oxygen. Mycopathologia. 2013;175(3–4):295–300.

    Article  Google Scholar 

  48. Almannai M, Imran H, Estrada B, Siddiqui AH. Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy. Pediatr Hematol Oncol. 2013;30(3):184–6.

    Article  PubMed  Google Scholar 

  49. Saedi B, Sadeghi M, Seilani P. Endoscopic management of rhinocerebral mucormycosis with topical and intravenous amphotericin B. J Laryngol Otol. 2011;125(8):807–10. doi:10.1017/S0022215111001289.

    Article  CAS  PubMed  Google Scholar 

  50. Raj P, Vella EJ, Bickerton RC. Successful treatment of rhinocerebral mucormycosis by a combination of aggressive surgical debridement and the use of systemic liposomal amphotericin B and local therapy with nebulized amphotericin b—a case repor. J Laryngol Otol. 1998;112(4):367–70.

    Article  CAS  PubMed  Google Scholar 

  51. Lass-Flörl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2008;52(10):3637–41. doi:10.1128/AAC.00662-08.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Nakai T, Uno J, Otomo K, Ikeda F, Tawara S, Goto T, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy. 2002;48(2):78–81.

    Article  CAS  PubMed  Google Scholar 

  53. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother. 1997;41(8):1835–6.

    PubMed Central  PubMed  Google Scholar 

  54. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36(10):2950–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  55. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41(8):3623–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008;198(2):186–92. doi:10.1086/589305.

    Article  CAS  PubMed  Google Scholar 

  57. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards Jr JE, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49(2):721–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51(7):2587–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Greenberg RN, Mulane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo study (2005-2007). Clin Infect Dis. 2012;54(1 Suppl):S35–43.

    Article  CAS  PubMed  Google Scholar 

  61. Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65(2):296–302.

    Article  CAS  PubMed  Google Scholar 

  62. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–67.

    Article  CAS  PubMed  Google Scholar 

  63. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18(6):660–7.

    Article  CAS  PubMed  Google Scholar 

  64. Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Investig. 1993;91(5):1979–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Lewis RE, Pongas GN, Albert N, Ben-Ami R, Walsh TJ, Kontoyiannis DP. Activity of deferasirox in Mucorales: influences of species and exogenous iron. Antimicrob Agents Chemother. 2011;55(1):411–3. doi:10.1128/AAC.00792-10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Exjade® [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 2013.

  67. Widmer F, Wright LC, Obando D, Handke R, Ganendren R, Ellis DH, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother. 2006;50(2):414–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Roze LV, Linz JE. Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol. 1998;25(2):119–33.

    Article  CAS  PubMed  Google Scholar 

  69. Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit. 2012;34:72–6.

    Article  PubMed  Google Scholar 

  70. Noxafil (posaconazole) injection 18 mg/mL. Whitehouse Station, NJ. Merck &Co., Inc; Revised. 2014.

  71. Krishna G, Ma L, Martinho M, Preston RA, O’Mara E. A new solid oral tablet formation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Angela M. Huang, Jerod L. Nagel, Ryan L. Crass, and Cynthia Nguyen declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Froedtert & The Medical College of Wisconsin, 9200 W. Wisconsin Ave, Milwaukee, WI, 53226, USA

    Angela M. Huang & Ryan L. Crass

  2. Department of Pharmacy Services and Clinical Services, University of Michigan Health System, 1111 E. Catherine St. Rm 300, Ann Arbor, MI, 48109, USA

    Jerod L. Nagel

  3. Department of Pharmacy, Ochsner Medical Center, 1514 Jefferson Highway, New Orleans, LA, 70121, USA

    Cynthia Nguyen

Authors
  1. Angela M. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerod L. Nagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryan L. Crass
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cynthia Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela M. Huang.

Additional information

This article is part of the Topical Collection on Pharmacology and Pharmacodynamics of Antifungal Agents

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, A.M., Nagel, J.L., Crass, R.L. et al. Combination Therapy for the Treatment of Mucormycosis: Examining the Evidence. Curr Fungal Infect Rep 9, 94–110 (2015). https://doi.org/10.1007/s12281-015-0222-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-015-0222-5

Keywords

Search

Navigation